Optimal Management for NSCLC Patients With Brain Metastasis
A Yale Cancer Center team completed a multi-institutional analysis of treatment options for patients with newly diagnosed EGFR-mutant non-small cell lung cancer (NSCLC) with brain metastases to determine the best option for treatment. Stereotactic radiosurgery, in combination with targeted therapy using EGFR tyrosine kinase inhibitors, resulted in the longest survival and best outcomes for patients. The findings were presented September 26 at the American Society for Therapeutic Radiology and Oncology (ASTRO) meeting in Boston.
This study analyzed three current options by reviewing outcomes of 351 patients from six institutions with EGFR-mutant NSCLC who were treated with either stereotactic radiosurgery in conjunction with targeted therapy (100), whole brain radiotherapy in conjunction with targeted therapy (120), or targeted therapy alone followed by stereotactic radiosurgery or whole brain radiotherapy if salvage was required (131).
To read more, click here.
2017 AANS/CNS Section on Pediatric Neurological Surgery
Nov. 28-Dec. 1, 2017; Houston
2nd Homburg ICP and Hydrocephalus Workshop
Nov. 28-30, 2017; Germany
22nd Instructional Course and 45th Annual Meeting of the Cervical Spine Research Society
Nov. 29, 2017 - Dec. 2, 2017; Hollywood, Fla.